Oncology

PSMA+ mCRPC

Advertisement

Conference Reporter® Podcast: Metastasis-Directed Therapy and Precision Radiation in Metastatic Prostate Cancer

conference reporter by Phuoc T. Tran, MD, PhD
Overview

Metastasis-directed therapy is reshaping care for select patients with oligometastatic and oligoprogressive prostate cancer, but optimal patient selection and treatment intensification remain active areas of investigation. In today’s podcast, Phuoc T. Tran, MD, PhD, discusses the evolving role of precision radiation, biomarkers, and radioligand therapy based on updates from the recent 2026 ASTRO Annual Meeting.

 

Following these presentations, featured expert Phuoc T. Tran, MD, PhD, was interviewed by Conference Reporter Editor-in-Chief Tom Iarocci, MD. Clinical perspectives from Dr Tran on these findings are presented here.

 

References

Grossman C, Bertolet A, Morris Z, Gitto S. The biology of radiopharmaceuticals (RPTs): beyond the physical properties [session: EDU 57]. Session presented at: 2026 American Society for Radiation Oncology Annual Meeting; September 26-30, 2026; Boston, MA.

 

Kishan AU, Valle LF, Wilhalme H, et al. 177Lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, phase II study. J Clin Oncol. 2025;43(36):3812-3821. doi:10.1200/JCO-25-01553

 

Niazi T, Saad F, Tisseverasinghe S, et al. Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025;26(9):1158-1167. doi:10.1016/S1470-2045(25)00351-1

 

Sutera P, Shetty A, Song Y, et al. Interpreting the model: biologic pathways underlying a clinically validated multimodal digital pathology AI biomarker in metastatic prostate cancer [abstract 316] [session: SS 36 – Predicting benefit and toxicity: biomarkers in prostate radiotherapy]. Abstract presented at: 2026 American Society for Radiation Oncology Annual Meeting; September 26-30, 2026; Boston, MA.

 

Tang C, Sherry AD, Haymaker C, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol. 2023;9(6):825-834. doi:10.1001/jamaoncol.2023.0161

 

Wang JH, Huang D, Amoateng EJ, et al. Metastasis-directed therapy in oligoprogressive prostate cancer: current evidence and future directions. Ann Palliat Med. 2026;15(4):64. doi:10.21037/apm-2026-0041

 

Wang JH, Sherry AD, Bazyar S, et al. Outcomes of radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: the RAVENS phase II randomized trial. J Clin Oncol. 2025;43(18):2059-2068. doi:10.1200/JCO-25-00131

 

This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society for Radiation Oncology.

Phuoc T. Tran, MD, PhD

Sally Cooper Murray Endowed Chair in Cancer Research
Professor and Chair
Department of Genitourinary Radiation Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Advertisement